Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biomed Res Int ; 2017: 9658018, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28473992

RESUMO

Purpose. Drug-induced liver injury (DILI) is the most common cause of liver injury and a serious clinical problem; antimycotics are involved in approximately 3% of all DILI cases. The hepatotoxicity of many drugs, including the antimycotics, is poorly screened in human models. Methods. In a standardized assay the cytotoxicity on hepatocytes of different concentrations (Cmax, 5x Cmax, and 10x Cmax) of the antimycotics used for systemic infections was tested. Anidulafungin (ANI), liposomal amphotericerin B (L-AmB), caspofungin (CASPO), fluconazole (FLUCO), and voriconazole (VORI) were incubated with HepG2/C3A cells. After incubation, the viability of cells (XTT test, LDH release, trypan blue staining), the synthesis of albumin, the cytochrome 1A2 activity, and the cell death (DNA fragmentation) were determined. Kruskal-Wallis and Mann-Whitney tests were used for statistical analyses. Results. L-AmB, ANI, and CASPO showed a mild hepatotoxicity in the Cmax concentrations. Higher concentrations of anidulafungin led to a severe impairment of hepatocyte viability and function. The azoles FLUCO and VORI had a higher hepatotoxic potential in all concentrations. Conclusion. Antimycotics, especially azoles, used for systemic infections should be given with caution in patient with liver insufficiency or liver failure or high risk for this; therefore, therapeutic drug monitoring should be used. Further studies with this approach are encouraged.


Assuntos
Antifúngicos/efeitos adversos , Hepatócitos/efeitos dos fármacos , Infecções Fúngicas Invasivas/tratamento farmacológico , Fígado/efeitos dos fármacos , Anidulafungina , Caspofungina , Doença Hepática Induzida por Substâncias e Drogas/complicações , Doença Hepática Induzida por Substâncias e Drogas/patologia , Equinocandinas/efeitos adversos , Fluconazol/efeitos adversos , Células Hep G2 , Hepatócitos/patologia , Humanos , Infecções Fúngicas Invasivas/complicações , Lipopeptídeos/efeitos adversos , Fígado/patologia , Voriconazol/efeitos adversos
2.
Biomed Res Int ; 2016: 7056492, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27433475

RESUMO

Purpose. Granulocyte transfusions have been used to treat immune cell dysfunction in sepsis. A granulocyte bioreactor for the extracorporeal treatment of sepsis was tested in a prospective clinical study focusing on the dosage of norepinephrine in patients and influence on dynamic and cell based liver tests during extracorporeal therapies. Methods and Patients. Ten patients with severe sepsis were treated twice within 72 h with the system containing granulocytes from healthy donors. Survival, physiologic parameters, extended hemodynamic measurement, and the indocyanine green plasma disappearance rate (PDR) were monitored. Plasma of patients before and after extracorporeal treatments were tested with a cell based biosensor for analysis of hepatotoxicity. Results. The observed mortality rate was 50% during stay in hospital. During the treatments, the norepinephrine-dosage could be significantly reduced while mean arterial pressure was stable. In the cell based analysis of hepatotoxicity, the viability and function of sensor-cells increased significantly during extracorporeal treatment in all patients and the PDR-values increased significantly between day 1 and day 7 only in survivors. Conclusion. The extracorporeal treatment with donor granulocytes showed promising effects on dosage of norepinephrine in patients, liver cell function, and viability in a cell based biosensor. Further studies with this approach are encouraged.


Assuntos
Circulação Extracorpórea/métodos , Fígado Artificial , Fígado/patologia , Norepinefrina/uso terapêutico , Sepse/patologia , Sepse/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/metabolismo , Contagem de Células , Estudos de Coortes , Citocromo P-450 CYP1A2 , Citocinas/metabolismo , Relação Dose-Resposta a Droga , Hemodinâmica , Células Hep G2 , Humanos , Inflamação/patologia , L-Lactato Desidrogenase/metabolismo , Testes de Função Hepática , Masculino , Pessoa de Meia-Idade , Norepinefrina/administração & dosagem , Análise de Sobrevida , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA